抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 2912人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1853045, encodeId=66681853045f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Am J Resp Crit Care：半乳糖凝集素-3抑制剂治疗COVID-19肺炎, objectType=article, longId=737448, objectId=f743e3744840, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f743e3744840, replyNumber=0, likeNumber=160, createdTime=2023-04-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f743e3744840, moduleTitle=Am J Resp Crit Care：半乳糖凝集素-3抑制剂治疗COVID-19肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f743e3744840)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853033, encodeId=98de18530335a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Cardiovasc Diabetol：SGLT2抑制剂在糖尿病合并心力衰竭患者中的当代应用情况, objectType=article, longId=736137, objectId=47e3e3613704, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47e3e3613704, replyNumber=0, likeNumber=182, createdTime=2022-11-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47e3e3613704, moduleTitle=Cardiovasc Diabetol：SGLT2抑制剂在糖尿病合并心力衰竭患者中的当代应用情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47e3e3613704)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853037, encodeId=3110185303e89, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率, objectType=article, longId=736657, objectId=c691e366579d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c691e366579d, replyNumber=0, likeNumber=169, createdTime=2022-11-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c691e366579d, moduleTitle=Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c691e366579d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853021, encodeId=9ad31853021a9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识, objectType=article, longId=732817, objectId=fd3ce32817fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd3ce32817fa, replyNumber=0, likeNumber=180, createdTime=2022-10-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd3ce32817fa, moduleTitle=Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd3ce32817fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853038, encodeId=d30818530387f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=君实生物JS110（XPO1抑制剂）临床试验申请获得美国FDA批准, objectType=article, longId=737116, objectId=19f3e3711610, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19f3e3711610, replyNumber=0, likeNumber=168, createdTime=2023-04-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19f3e3711610, moduleTitle=君实生物JS110（XPO1抑制剂）临床试验申请获得美国FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19f3e3711610)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853043, encodeId=8fbe185304314, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=肿瘤治疗过程中，务必慎用质子泵抑制剂！, objectType=article, longId=737351, objectId=9b06e3735173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b06e3735173, replyNumber=0, likeNumber=153, createdTime=2023-08-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b06e3735173, moduleTitle=肿瘤治疗过程中，务必慎用质子泵抑制剂！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b06e3735173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853002, encodeId=b66b1853002f9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, objectType=article, longId=730361, objectId=69abe303613d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69abe303613d, replyNumber=0, likeNumber=204, createdTime=2022-09-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69abe303613d, moduleTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69abe303613d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853041, encodeId=a182185304182, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ARD：超3万数据研究：TNF抑制剂、阿巴西普、IL6抑制剂和JAK抑制剂类风湿性关节炎患者中的有效性, objectType=article, longId=737269, objectId=eb97e3726901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb97e3726901, replyNumber=0, likeNumber=145, createdTime=2023-08-10, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb97e3726901, moduleTitle=ARD：超3万数据研究：TNF抑制剂、阿巴西普、IL6抑制剂和JAK抑制剂类风湿性关节炎患者中的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb97e3726901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853049, encodeId=2aa71853049c7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=治疗SLE常用的细胞毒免疫抑制剂, objectType=article, longId=738407, objectId=eae9e38407bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae9e38407bb, replyNumber=0, likeNumber=163, createdTime=2023-04-01, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae9e38407bb, moduleTitle=治疗SLE常用的细胞毒免疫抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae9e38407bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853030, encodeId=c5a4185303097, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险, objectType=article, longId=735642, objectId=ed39e3564211, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed39e3564211, replyNumber=0, likeNumber=149, createdTime=2023-05-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed39e3564211, moduleTitle=Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed39e3564211)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853031, encodeId=b8381853031bd, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JITC：突破性进展！开发出一种有望使免疫疗法适用于所有癌症患者的小分子PD-1/PD-L1抑制剂, objectType=article, longId=736109, objectId=7fe7e3610956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fe7e3610956, replyNumber=0, likeNumber=146, createdTime=2023-03-21, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fe7e3610956, moduleTitle=JITC：突破性进展！开发出一种有望使免疫疗法适用于所有癌症患者的小分子PD-1/PD-L1抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fe7e3610956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853050, encodeId=da3018530503a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=【每日播报】-磺脲类药物联合α-糖苷酶抑制剂的疗效, objectType=article, longId=738850, objectId=a364e388504c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a364e388504c, replyNumber=0, likeNumber=120, createdTime=2023-05-31, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a364e388504c, moduleTitle=【每日播报】-磺脲类药物联合α-糖苷酶抑制剂的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a364e388504c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853014, encodeId=849b185301435, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Cancers：免疫检查点抑制剂治疗期间免疫相关内分泌不良事件的临床表现, objectType=article, longId=731465, objectId=fe93e3146570, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe93e3146570, replyNumber=0, likeNumber=132, createdTime=2022-07-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe93e3146570, moduleTitle=Cancers：免疫检查点抑制剂治疗期间免疫相关内分泌不良事件的临床表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe93e3146570)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853023, encodeId=630f18530233d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=新型 p38 丝裂原活化蛋白激酶抑制剂可逆转缺氧诱导的大鼠肺动脉高压, objectType=article, longId=733923, objectId=b021e339232f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b021e339232f, replyNumber=0, likeNumber=147, createdTime=2022-10-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b021e339232f, moduleTitle=新型 p38 丝裂原活化蛋白激酶抑制剂可逆转缺氧诱导的大鼠肺动脉高压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b021e339232f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852982, encodeId=8def1852982ba, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效, objectType=article, longId=727754, objectId=ef63e277540f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef63e277540f, replyNumber=0, likeNumber=145, createdTime=2023-04-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef63e277540f, moduleTitle=Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef63e277540f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852959, encodeId=dde8185295952, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=A&R：肿瘤坏死因子抑制剂治疗与轴性脊柱关节炎患者影像学骶髂关节炎进展的时移延迟相关, objectType=article, longId=725982, objectId=0af7e25982c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0af7e25982c5, replyNumber=0, likeNumber=148, createdTime=2022-12-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0af7e25982c5, moduleTitle=A&R：肿瘤坏死因子抑制剂治疗与轴性脊柱关节炎患者影像学骶髂关节炎进展的时移延迟相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0af7e25982c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852968, encodeId=3e0218529686b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=A&R：细胞周期蛋白依赖性激酶4/6抑制剂对系统性硬化小鼠模型皮肤纤维化的治疗作用, objectType=article, longId=727078, objectId=5e3fe2707805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e3fe2707805, replyNumber=0, likeNumber=162, createdTime=2023-03-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e3fe2707805, moduleTitle=A&R：细胞周期蛋白依赖性激酶4/6抑制剂对系统性硬化小鼠模型皮肤纤维化的治疗作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e3fe2707805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853006, encodeId=720e1853006c6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Gastroenterology：质子泵抑制剂暴露与肝硬化患者感染与失代偿之间的关联, objectType=article, longId=730499, objectId=e40fe3049995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e40fe3049995, replyNumber=0, likeNumber=143, createdTime=2022-06-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e40fe3049995, moduleTitle=Gastroenterology：质子泵抑制剂暴露与肝硬化患者感染与失代偿之间的关联, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e40fe3049995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853007, encodeId=d303185300e71, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Immunol：HBV感染肝癌患者接受PD-1抑制剂联合治疗时HBV DNA和乙肝表面抗原水平与肿瘤疗效、肝功能和免疫学指标的相关性, objectType=article, longId=730662, objectId=e010e3066291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e010e3066291, replyNumber=0, likeNumber=140, createdTime=2022-07-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e010e3066291, moduleTitle=Front Immunol：HBV感染肝癌患者接受PD-1抑制剂联合治疗时HBV DNA和乙肝表面抗原水平与肿瘤疗效、肝功能和免疫学指标的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e010e3066291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852975, encodeId=d10618529e598, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=初始安立生坦联合5型磷酸二酯酶抑制剂对重度肺动脉高压患者右心室肺动脉耦合的超声心动图评估, objectType=article, longId=727539, objectId=b864e275392b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b864e275392b, replyNumber=0, likeNumber=195, createdTime=2022-10-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b864e275392b, moduleTitle=初始安立生坦联合5型磷酸二酯酶抑制剂对重度肺动脉高压患者右心室肺动脉耦合的超声心动图评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b864e275392b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Am J Resp Crit Care：半乳糖凝集素-3抑制剂治疗COVID-19肺炎

2023-04-18

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Cardiovasc Diabetol：SGLT2抑制剂在糖尿病合并心力衰竭患者中的当代应用情况

2022-11-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率

2022-11-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识

2022-10-07

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

君实生物JS110（XPO1抑制剂）临床试验申请获得美国FDA批准

2023-04-23

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

肿瘤治疗过程中，务必慎用质子泵抑制剂！

2023-08-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌

2022-09-07

heli0118 (审核中...)

前往app查看评论内容

#抑制剂#

ARD：超3万数据研究：TNF抑制剂、阿巴西普、IL6抑制剂和JAK抑制剂类风湿性关节炎患者中的有效性

2023-08-10

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

治疗SLE常用的细胞毒免疫抑制剂

2023-04-01

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险

2023-05-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JITC：突破性进展！开发出一种有望使免疫疗法适用于所有癌症患者的小分子PD-1/PD-L1抑制剂

2023-03-21

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

【每日播报】-磺脲类药物联合α-糖苷酶抑制剂的疗效

2023-05-31

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Cancers：免疫检查点抑制剂治疗期间免疫相关内分泌不良事件的临床表现

2022-07-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

新型 p38 丝裂原活化蛋白激酶抑制剂可逆转缺氧诱导的大鼠肺动脉高压

2022-10-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效

2023-04-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

A&R：肿瘤坏死因子抑制剂治疗与轴性脊柱关节炎患者影像学骶髂关节炎进展的时移延迟相关

2022-12-28

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

A&R：细胞周期蛋白依赖性激酶4/6抑制剂对系统性硬化小鼠模型皮肤纤维化的治疗作用

2023-03-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Gastroenterology：质子泵抑制剂暴露与肝硬化患者感染与失代偿之间的关联

2022-06-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Immunol：HBV感染肝癌患者接受PD-1抑制剂联合治疗时HBV DNA和乙肝表面抗原水平与肿瘤疗效、肝功能和免疫学指标的相关性

2022-07-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

初始安立生坦联合5型磷酸二酯酶抑制剂对重度肺动脉高压患者右心室肺动脉耦合的超声心动图评估

2022-10-04

科室
- - 订阅+
  - 更多科室
工具
服务